NEWARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) — Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies for the treatment of cancer announced today that it has received orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma.
Read more
GENEVA & NEWARK, Calif.–(BUSINESS WIRE)–Selexis SA and Teneobio, Inc. announced today that they have signed three commercial license agreements (CLAs) for the development of Teneobio’s Human Heavy-Chain Antibodies (UniAbs®), a new class of multi-specific biologics, for the treatment of multiple myeloma, lymphoma and prostate cancer. The CLAs expand the companies’ previously established relationship, including a service agreement signed between Teneobio and Selexis in December 2018.
Read more
NEWARK, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) — Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies for the treatment of cancer announced today that as a result of its work with scientists from Janssen Research & Development, LLC, Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has elected to exercise a commercial option to license and advance an undisclosed multispecific product for development in an oncology indication.
Read more
NEWARK, Calif., July 15, 2019 (GLOBE NEWSWIRE) — Teneobio, Inc. a clinical-stage biotechnology company developing engineered bispecific antibodies for the treatment of cancer announced today that the first patient has been dosed with TNB-383B in a Phase 1 clinical study to evaluate the safety and tolerability of its differentiated anti-BCMAxCD3, a bispecific antibody that redirects T-cells to kill multiple myeloma cells with minimal cytokine release.
Read more
NEWARK, Calif., April 29, 2019 (GLOBE NEWSWIRE) — Teneobio, Inc. and its affiliate TeneoOne, Inc. announced today that their investigational new drug application (IND) for TNB-383B, a bispecific T-cell engaging antibody for the treatment of multiple myeloma, was cleared for the initiation of Phase I clinical studies by the US Food and Drug Administration (FDA) on April 24th, 2019. The ongoing development of TNB-383B is being pursued in collaboration with AbbVie, Inc.
Read more
NORTH CHICAGO, Ill. and MENLO PARK, Calif., Feb. 11, 2019 /PRNewswire/ — AbbVie (NYSE: ABBV), Teneobio, Inc. and its affiliate TeneoOne, Inc. announced today that they have entered a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma.
Read more